

## Veletri - (0.5,1.5 mg; Injectable, Injection)

<b>Generic Name</b>	Epoprostenol Sodium	<b>Innovator</b>	ACTELION
<b>Dosage</b>	0.5,1.5 mg; Injectable, Injection	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.